<DOC>
	<DOC>NCT00652041</DOC>
	<brief_summary>Multicentric study, open, single arm, designed to evaluate the efficacy(response rate and response duration) and security of a sequential scheme of treatment with Bortezomib in combination with Melfalan and Prednisone (V-MP) (patients &gt; 75 years) or Bortezomib and Adriamycine in combination with Melfalan and Prednisone (VAMP) (patients &lt;= 75 years) follow by Thalidomide in combination with Cyclophosphamide and Dexamethasone (TaCyDex) in patients with refractary or relapse multiple myeloma.</brief_summary>
	<brief_title>Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma</brief_title>
	<detailed_description>Multicentric study, open, single arm, designed to evaluate the efficacy(response rate and response duration) and security of a sequential scheme of treatment with Bortezomib in combination with Melfalan and Prednisone (V-MP) (patients &gt; 75 years) or Bortezomib and Adriamycine in combination with Melfalan and Prednisone (VAMP) (patients &lt;= 75 years) follow by Thalidomide in combination with Cyclophosphamide and Dexamethasone (TaCyDex) in patients with refractary or relapse multiple myeloma.</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients with refractary or relapsed multiple myeloma ECOG ≤ 3 Life expectancy &gt; 3 months Neutrophils account ≥ 0.5 X 10^9/L, platelets ≥ 30 X 10^9/L. Transaminases &lt;3 times upper normal limit, bilirubin &lt; 2 times upper normal limit Age &gt; 18 years Time after last chemotherapy or radiotherapy &gt; 1 month or time after transplantation &gt; 2 months. No possible other actual treatment Written consent form Candidate to second transplantation No following criteria Other neoplasties Peripheral neuropathy &gt; Grade 2. Previous ileus paralytic Hepatic failure No controlled infection No controlled high calcium levels Any organic insufficiency that no permit follow the correct treatment Pregnancy, breast feeding or fertility without anticonceptive method Any psychological, social and/or familiar event that no permit follow the correct treatment Diabetes mellitus not controled</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractary</keyword>
</DOC>